USFDA gives assent to Zydus Cadila for marketing capsules to treat heart rhythm disorder

Zydus Cadila informed today that it has received approval from USFDA to market Propafenone Hydrochloride extended-release capsules. 

The above-mentioned capsules are prescribed to certain people who have a heart rhythm disorder called Atrial fibrillation (AF). The pharma company has received final approval for marketing Propafenone Hydrochloride extended-release capsules USP, 225 mg, 325 mg, and 425 mg (US RLD: Rythmol capsules). Propafenone is an antiarrhythmic drug. It works by obstructing the activity of certain electrical signals in the heart, which can lead to an irregular heartbeat.   

Zydus Cadila will manufacture the drug at its formulation manufacturing facility located at SEZ, Ahmedabad. The group reports having 315 approvals and so far, has over 400 abbreviated new drug applications (ANDAs) since the initiation of its filing process in FY 2003-04. 

Zydus Cadila is a leading Indian pharmaceutical company with in-depth domain expertise in the field of healthcare. Its products range from formulations to APIs along with animal healthcare products to wellness products. The company has earned a reputation amongst Indian pharmaceutical companies for catering to the needs with comprehensive and complete healthcare solutions. 

In spite of positive development, on Friday, the share of Zydus Cadila was trading 1.27 per cent down at Rs 545.55 on BSE. Meanwhile, on Thursday, the stock had hit its fresh 52-week high.